Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Orasense
Fort Lauderdale, Florida, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
OraSense was a biotechnology company focused on the development of saliva-based diagnostic tests for the early detection of oral cancer. The company's primary technology utilized biomarkers such as CD44 and total protein levels to identify patients at high risk for oral and oropharyngeal squamous cell carcinoma. Founded by Matthew H.J. Kim, the company aimed to provide a non-invasive, point-of-care solution to improve survival rates through earlier diagnosis. OraSense eventually served as the foundation for the establishment of Vigilant Biosciences, which continued the development and commercialization of the saliva-based oncological diagnostic platform.
- Therapeutic areas
- Oncology
- Modalities
- DiagnosticBiomarker-based assay
- Industry
- Protein Biomarker Diagnostics
02
Partnerships
University of Miami
Beyond the preview
Go deeper on Orasense.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orasense.